Preclinical Characterization of the
177Lu-labeled antibody
CHX-A″-DTPA
prostate cancer
prostate stem cell antigen
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 May 2023
29 May 2023
Historique:
received:
26
04
2023
revised:
20
05
2023
accepted:
23
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Prostate specific membrane antigen (PSMA) is an excellent target for imaging and treatment of prostate carcinoma (PCa). Unfortunately, not all PCa cells express PSMA. Therefore, alternative theranostic targets are required. The membrane protein prostate stem cell antigen (PSCA) is highly overexpressed in most primary prostate carcinoma (PCa) cells and in metastatic and hormone refractory tumor cells. Moreover, PSCA expression positively correlates with tumor progression. Therefore, it represents a potential alternative theranostic target suitable for imaging and/or radioimmunotherapy. In order to support this working hypothesis, we conjugated our previously described anti-PSCA monoclonal antibody (mAb) 7F5 with the bifunctional chelator CHX-A″-DTPA and subsequently radiolabeled it with the theranostic radionuclide
Identifiants
pubmed: 37298374
pii: ijms24119420
doi: 10.3390/ijms24119420
pmc: PMC10253363
pii:
doi:
Substances chimiques
Pentetic Acid
7A314HQM0I
Antibodies, Monoclonal
0
Lutetium
5H0DOZ21UJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Biother Radiopharm. 2015 Aug;30(6):240-6
pubmed: 26066665
Sci Rep. 2018 Jun 12;8(1):8960
pubmed: 29895866
Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):312-5
pubmed: 12552352
Oncoimmunology. 2020 Jul 3;9(1):1785608
pubmed: 32923149
PLoS One. 2014 Apr 03;9(4):e93745
pubmed: 24699869
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
Cancer Res. 2002 May 1;62(9):2546-53
pubmed: 11980648
J Labelled Comp Radiopharm. 2019 Apr;62(4):158-165
pubmed: 30663095
J Autoimmun. 2013 May;42:105-16
pubmed: 23352111
J Labelled Comp Radiopharm. 2016 Jul;59(9):354-63
pubmed: 27264196
J Nucl Med. 2018 Sep;59(9):1406-1411
pubmed: 29371407
Oncol Lett. 2017 May;13(5):3347-3353
pubmed: 28521441
J Cell Biol. 1976 Oct;71(1):159-71
pubmed: 977646
PLoS One. 2012;7(6):e38350
pubmed: 22761679
Cancer Lett. 2006 May 18;236(2):229-38
pubmed: 16046056
Oncol Lett. 2018 Mar;15(3):3081-3084
pubmed: 29435040
Front Oncol. 2019 Sep 11;9:884
pubmed: 31572678
Tomography. 2015 Dec;1(2):81-84
pubmed: 26807444
J Nucl Med. 1990 Jul;31(7):1191-8
pubmed: 2362198
J Autoimmun. 2018 Jun;90:116-131
pubmed: 29503042
Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157632
pubmed: 36895851
J Urol. 2004 Mar;171(3):1117-21
pubmed: 14767283
J Nucl Med. 2018 Jul;59(7):1076-1080
pubmed: 29269569
Semin Nucl Med. 2011 Jan;41(1):29-44
pubmed: 21111858
Radiology. 2007 Apr;243(1):28-53
pubmed: 17392247
Nucl Med Biol. 2010 Oct;37(7):741-50
pubmed: 20870149
Oncotarget. 2018 May 22;9(39):25597-25616
pubmed: 29876011
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2658-63
pubmed: 11226295
Oncotarget. 2017 Apr 29;8(33):54592-54603
pubmed: 28903367
Nucl Med Biol. 2006 Nov;33(8):991-8
pubmed: 17127172
J Nucl Med. 1995 Oct;36(10):1902-9
pubmed: 7562062
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Cancer Res. 2006 Mar 15;12(6):1665-71
pubmed: 16551847
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670
pubmed: 28624848
Cancer Immunol Immunother. 2019 Oct;68(10):1713-1719
pubmed: 31542798
J Med Chem. 2018 Oct 11;61(19):8774-8796
pubmed: 30180567
Cancer Res. 2005 Oct 15;65(20):9495-500
pubmed: 16230414
Cancer Biother Radiopharm. 2009 Apr;24(2):155-61
pubmed: 19409036
Chem Soc Rev. 2016 Nov 21;45(23):6415-6431
pubmed: 27722526
Radiographics. 2016 Jan-Feb;36(1):142-59
pubmed: 26587888
Nat Rev Drug Discov. 2004 Jun;3(6):488-99
pubmed: 15173838
Pharmaceuticals (Basel). 2014 Jun 30;7(7):779-96
pubmed: 24983957
J Nucl Med. 2017 Oct;58(10):1553-1559
pubmed: 28687600
J Nucl Med. 2018 May;59(5):747-748
pubmed: 29439016
Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304
pubmed: 15640793
Immunol Lett. 2019 Jul;211:13-22
pubmed: 31091431
Prostate. 2014 Sep;74(13):1335-46
pubmed: 25053443
J Immunol. 2012 Sep 15;189(6):3249-59
pubmed: 22875801
Cancer Res. 1992 Feb 15;52(4):904-11
pubmed: 1737353
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
Oncotarget. 2017 May 9;8(19):31368-31385
pubmed: 28404896
Clin Nucl Med. 2017 Feb;42(2):152-153
pubmed: 27922871
J Med Imaging Radiat Oncol. 2016 Aug;60(4):514-7
pubmed: 26394552
Pathol Oncol Res. 2009 Jun;15(2):167-72
pubmed: 18802790
Clin Cancer Res. 2005 Apr 1;11(7):2591-6
pubmed: 15814638
Tomography. 2018 Dec;4(4):182-193
pubmed: 30588504
Oncotarget. 2017 Aug 2;8(39):66112-66116
pubmed: 29029496
J Biomol Screen. 2016 Jan;21(1):12-23
pubmed: 26518032
Curr Radiopharm. 2015;8(2):78-85
pubmed: 25771380
Prostate. 2011 Jun 15;71(9):998-1011
pubmed: 21541976
Clin Nucl Med. 2016 Apr;41(4):331-2
pubmed: 26646999
Oncogene. 2000 Mar 2;19(10):1288-96
pubmed: 10713670
Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1457-62
pubmed: 16193312
Curr Radiopharm. 2015;8(2):139-44
pubmed: 25771372
Cancers (Basel). 2012 Feb 22;4(1):193-217
pubmed: 24213236
Oncotarget. 2019 Oct 22;10(58):6124-6137
pubmed: 31693724
Prostate. 2007 Jul 1;67(10):1121-31
pubmed: 17492652
Oncoimmunology. 2019 Sep 7;8(11):1659095
pubmed: 31646084
Clin Nucl Med. 2016 Jul;41(7):522-8
pubmed: 27088387
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
J Labelled Comp Radiopharm. 2019 Jun 30;62(8):533-540
pubmed: 30889625